China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
China Resources Pharmaceutical Group Ltd. is undergoing an internal reorganization aimed at enhancing its influence in the panax notoginseng industry by selling a 51% stake in CR Shenghuo to KPC for RMB1,791 million. This move is part of the company’s strategic plan to optimize its industrial chain and resolve competition issues, promising enhanced synergy and improved market presence for its traditional Chinese medicine products.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
